Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice

American Journal of Pathology

Volumn 159, Issue 2, 2001, Pages 513-525

  Goova, Mouza T ^a   Li, Jun ^a   Kislinger, Thomas ^a   Qu, Wu ^a   Lu, Yan ^a   Bucciarelli, Loredana G ^a   Nowygrod, Sarah ^a   Wolf, Bonnie M ^a   Caliste, Xzabia ^a   Yan, Shi Fang ^a   Stern, David M ^a   Schmidt, Ann Marie ^a  

^a The New York Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CYTOKINE; GELATINASE A; GELATINASE B; INTERLEUKIN 6; LIGAND; PLATELET DERIVED GROWTH FACTOR B; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CYTOKINE PRODUCTION; DIABETES MELLITUS; GRANULATION TISSUE; INFLAMMATORY CELL; LIGAND BINDING; MALE; MICROVASCULARIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RECEPTOR BLOCKING; WOUND HEALING IMPAIRMENT;

EID: 0034880114     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)61723-3     Document Type: Article

References (46)

1. Wound healing and the diabetic patient
2. Wound healing in diabetes mellitus
3. Studies of wound healing in experimental diabetes
4. Cell biology of wound healing
5. The physiology of wound healing. A summary of normal and abnormal wound healing processes
6. Blood bactericidal studies and serum complement in diabetic patients
7. Effects of hyperglycemia on survival of bacteria
8. Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis and intracellular bacterial killing
9. Wound collagen accumulation in obese hyperglycemic mice
10. In vivo collagen metabolism in spontaneously diabetic (db/db) mice
11. Decreased platelet mitogenic activity in patients with diabetes mellitus
12. PDGF and FGF stimulate wound healing in the genetically diabetic mouse
13. Abnormalities of granulation tissue and collagen formation in experimental diabetes, uremia, and malnutrition
14. Wound collagenase activity correlates directly with collagen glycosylation in diabetic rats
15. Mitogenic activity and cytokine levels in non-healing and healing chronic leg ulcers
16. Streptozotocin diabetes: Prolonged inflammatory response with delay in granuloma formation
17. Large and sustained induction of chemokines during impaired wound healing in diabetic mouse: Prolonged persistence of neutrophils and macrophages during the late phase of repair
18. Isolation and characterization of binding proteins for advanced glycosylation endproducts from lung tissue which are present on the endothelial cell surface
19. Cloning and expression of RAGE: A cell surface receptor for advanced glycosylation end products of proteins
20. Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE)
21. Blockade of RAGE suppresses periodontitis-associated alveolar bone loss in diabetic mice
22. The dark side of glucose (news and views)
23. The expression of advanced glycation endproducts and their cellular receptor RAGE in diabetic nephropathy and non-diabetic renal disease
24. RAGE mediates a novel proinflammatory axis: A central cell surface receptor for S100/calgranulin polypeptides
25. ε (carboxymethyl)lysine modifications of proteins are ligands for RAGE that activate cell signalling pathways and modulate gene expression
26. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties
27. Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins
28. AGE interaction with their endothelial receptor induce expression of VCAM-1: A potential mechanism for the accelerated vasculopathy of diabetes
29. Regulation of mononuclear phagocyte migration by cell surface binding proteins for advanced glycosylation endproducts
30. 2-microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway: Implications for the pathogenesis of dialysis-related amyloidosis
31. 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts
32. Non-enzymatic glycation of epidermal proteins of the stratum corneum in diabetic patients
33. Increased accumulation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in human tissues in diabetes and aging
34. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: Relevance of glycated collagen products versus HbA1c as markers of diabetic complications. Diabetes Control and Complications Trial
35. Diabetes - Obesity syndromes in mice
36. The influence of age and dietary conditions on diabetes in the db mouse
37. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation endproducts blocks hyperpermeability
38. Interactions of cytokines, growth factors, and proteases in acute and chronic wounds
39. Analysis of the acute and chronic wound environments: The role of proteases and their inhibitors
40. Gelatinase activities in wounds of healing-impaired mice versus wounds of non-healing impaired mice
41. Molecular and mechanistic validation of delayed healing rat wounds as a model for human chronic wounds
42. Apoptosis down-regulates inflammation under the advancing epithelial wound edge: Delayed patterns in diabetes and improvement with topical growth factors
43. Expression and localization of p53 and bcl-2 in healing wounds in diabetic and nondiabetic mice
44. The role of growth factors in wound healing
45. Clinical efficacy of becaplermin (rhPDGF-B) gel
46. Recombinant human platelet-derived growth factor-B (becaplermin) for healing chronic lower extremity diabetic ulcers: An open-label clinical evaluation of efficacy